Ustekinumab, a fully human IgG1 antibody targeting the shared p40 subunit of both IL-23 and IL-12, achieved 15.6% week 8 remission (6 mg/kg IV induction) versus 5.3% placebo and 43.8% week 44 remission (90mg SC every 812 weeks) versus 24.0% placebo in UNIFI trials ( Next-generation anti-interleukin strategies employ innovative approaches: oral peptide IL-23 receptor antagonists with gut-selective blockade and picomolar affinity (icotrokinra), optimized IL-23p19 inhibitors (picankibart, brazikumab), selective gp130 trans-signaling inhibitors preserving classical IL-6 signaling (olamkicept), IL-4R antagonists for type 2-driven disease (dupilumab), IL-36 receptor antagonists (spesolimab), CD127/IL-7R antagonists (lusvertikimab), IL-1 neutralizing antibodies (lutikizumab), and IL-13-specific inhibitors (anrukinzumab, tralokinumab)
Mogroside V protects porcine oocytes from in vitro ageing by reducing oxidative stress through SIRT1 upregulation
Storage guidelines differ between multi-dose pens and single-dose devices , and it's important to understand which type of device you're using
In this blogpost: Levels of Uric Acid and Glutathione During Brief Exposure Whole Body Cold exposure The study looked at ten healthy people who regularly swim in ice-cold water during the winter
2021 (9) CD007662
If you are experiencing side effects that make you reluctant to continue treatment , such as persistent nausea, vomiting, or gastrointestinal discomfort, discuss these openly with your healthcare provider rather than simply missing doses